EVAX Evaxion Biotech A/S ADRs

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$8.10  +0.05 (0.62%)
As of 10/19/2021 13:13:25 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Denmark
Country of incorporation:  
IPO date:  02/04/2021
Outstanding shares:  19,198,668
Average volume:  31,836
Market cap:   $152,053,451
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    29970R105
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   -4.12
PS ratio:   0.00
Return on equity:   51.22%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy